Scleroderma is a complex autoimmune disease characterized by connective tissue damage and chronic inflammation, which leads to excessive collagen production. As a result of this process, changes develop in the skin, internal organs, and blood vessels. The clinical manifestations of scleroderma can vary significantly, including symptoms such as thickening of the skin, limited joint mobility, and functional disorders of internal organs. This disease has two main forms: limited and diffuse scleroderma, each of which has its own clinical picture and possible consequences.
History of the disease and interesting historical facts
Scleroderma has been known since ancient times, and its description can be found in the writings of Hippocrates, who observed the skin manifestations of the disease. Over the centuries, the term "scleroderma" has changed, from "sclerosis of the skin" to the current, more comprehensive understanding of the disease. In the 19th century, thanks to the work of scientists such as Raynaud and Gierod, scleroderma began to be studied in more detail, which contributed to the identification of its classification system. An interesting aspect of scleroderma research is that it mainly affects women, with the ratio of cases among women to men being approximately 4:1. An important step in the study of the disease has been the creation of a number of international registries that allow the study and generalization of clinical data on patients with this diagnosis.
Epidemiology
Scleroderma has a very low prevalence, with reported incidence rates ranging from 0.5 to 4 cases per 100,000 population per year. The disease is more common in women, especially those aged 30-50 years. However, according to different sources, the total number of cases of scleroderma in a population may vary; in some countries, up to 300 cases per 100,000 people are registered. It is important to note that in areas with high solar activity and among populations exposed to certain chemicals, the incidence may be higher, as confirmed by epidemiological studies.
Genetic predisposition to this disease
There is evidence of a genetic predisposition to scleroderma determined by multiple genes. Studies indicate the involvement of genes such as HLA-DRB1 and HLA-DQB1, which play a key role in the cellular immune response. The multifactorial nature of the disease is also supported by associations with certain mutations in genes responsible for immune regulation and collagen synthesis. For example, mutations in the COL1A1 gene, which is responsible for collagen synthesis, may increase the risk of developing the disease. Studies have shown that a family history of scleroderma is observed in approximately 5-12% patients, which also confirms a genetic component.
Risk factors for the development of this disease
Scleroderma is associated with multiple risk factors, which can be divided into physical and chemical. Physical factors include:
- The influence of ultraviolet radiation.
- Skin injuries and chronic skin diseases.
Chemical risk factors include:
- Effects of silicosis.
- Exposure to chemicals such as solvents and pesticides.
In addition, cosmetic products containing certain chemical components may also contribute to the development of the disease. It is important to note that some infectious agents, such as viruses and bacteria, can activate autoimmune processes, leading to scleroderma.
Diagnosis of this disease
Diagnosis of scleroderma is a complex process based on clinical manifestations and additional examinations. The main symptoms of the disease include:
- Thickening and discoloration of the skin.
- Impaired joint mobility.
- Damage to internal organs such as the lungs, heart, kidneys and gastrointestinal tract.
Laboratory tests are used to confirm the diagnosis, including antibody testing such as ANA, anti-Scl-70, and anti-centromere antibodies, which aid in differential diagnosis. Radiological examinations such as chest X-ray and cardiac ultrasound, as well as other imaging techniques, help identify changes in internal organs. The diagnosis also requires differential diagnosis with conditions such as systemic lupus erythematosus and dermatomyositis.
Treatment
Treatment of scleroderma depends on the severity of the condition and clinical manifestations. It can be divided into general, pharmacological and surgical treatment, as well as other auxiliary methods.
General treatment includes:
- Maintaining a physical activity regimen.
- Patient support and counseling.
Pharmacological treatment may include:
- Immunosuppressants (eg, methotrexate).
- Glucocorticosteroids.
- Vasodilators to improve microcirculation.
Surgery is used for major organ damage, such as lung or other limb transplants. Other treatments include physical therapy and psychotherapy to manage chronic pain and depression that often accompany the disease.
List of medications used to treat this disease
The main drugs used in the treatment of scleroderma include:
- Methotrexate.
- Cyclophosphamide.
- Mycophenolate mofetil.
- Remicade (infliktimab).
- Plakinil (hydroxychloroquine).
- Losartan.
Each of these agents has a specific mechanism of action and is used depending on the clinical situation and the severity of the disease.
Disease monitoring
Monitoring scleroderma requires regular assessment of the patient's condition. Monitoring steps include:
- Regular check-ups with a dermatologist and other specialists.
- Conducting laboratory tests for disease activity and side effects from therapy.
- Assessment of the state of functional organ systems.
The prognosis of the disease varies depending on the form and severity of the disease. Complications such as pulmonary hypertension, renal failure are possible, which can significantly worsen the patient's quality of life. Timely detection and treatment of these complications is extremely important.
Age-related features of the disease
Scleroderma can manifest itself differently depending on the age category. In young patients, as a rule, a more aggressive course of the disease and more pronounced skin changes are observed, while in older patients, a milder form and expression of systemic manifestations are often observed. In children and adolescents, scleroderma occurs less often and, as a rule, has a less severe course.
Questions and Answers
- What is scleroderma? It is an autoimmune disease that causes an increase in collagen and leads to changes in the skin and internal organs.
- What are the main symptoms of scleroderma? Thickening of the skin, limited joint movement, and damage to internal organs.
- What are the risk factors for developing scleroderma? Chemical exposure, ultraviolet radiation and genetic predisposition.
- How is scleroderma diagnosed? Based on clinical manifestations, laboratory tests for antibodies and radiological examinations.
- What treatments are available for scleroderma? Treatment includes pharmacological agents, surgical interventions and general supportive measures.
